Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I)

BACKGROUND: Liver transplantation is the definitive treatment for many end-stage liver diseases. However, the life-long immunosuppression needed to prevent graft rejection causes clinically significant side effects. Cellular immunomodulatory therapies may allow the dose of immunosuppressive drugs to...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Popp, Felix C, Fillenberg, Barbara, Eggenhofer, Elke, Renner, Philipp, Dillmann, Johannes, Benseler, Volker, Schnitzbauer, Andreas A, Hutchinson, James, Deans, Robert, Ladenheim, Deborah, Graveen, Cheryl A, Zeman, Florian, Koller, Michael, Hoogduijn, Martin J, Geissler, Edward K, Schlitt, Hans J, Dahlke, Marc H
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2011
Teme:
Protocol
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3166276/
https://ncbi.nlm.nih.gov/pubmed/21798013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-9-124
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki